EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia

Nikolai A Podoltsev iD, Rong Wang, Rory M Shallis iD, Jessica M Stempel, Mengyang Di, Natalia Neparidze, Amer M Zeidan, Scott F Huntington iD, Smith Giri iD, Sarah C Hull, Steven D Gore, Xiaomei Ma

Cancer Medicine · 2023-09 · 12 (18) · 18889-18900

DOI: 10.1002/cam4.6528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 13.09.2023. Verfasst von Nikolai A Podoltsev und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Polycythemia Vera, Thrombocythemia, Essential, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Thrombosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCCDPHP CDC HHS, NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycythemia vera (PV) and essential thrombocythemia (ET) are linked to increased risk of cardiovascular morbidity and mortality. In addition to the reduction in of arterial thrombotic events, statins may prevent venous thrombosis including among patients with cancer. As previous registry‐ and claims‐based studies revealed that the use of statins may improve the survival of patients with various malignancies we evaluated their impact on outcomes of older adults with PV and ET.

Methods

We identified 4010 older adults (aged 66–99 years at diagnosis) with PV ( n = 1809) and ET ( n = 2201) in a population‐based cohort study using the Surveillance, Epidemiology, and End Results‐Medicare database with median follow‐up of 3.92 (interquartile range: 2.58–5.75) years. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) approaches were utilized to assess potential association between statins and overall survival. Multivariable competing risk models with death as a competing risk were used to evaluate possible relationship between statins and the incidence of thrombosis.

Results

55.8% of the patients used statins within the first year after PV / ET diagnosis, and statin use was associated with a 22% reduction in all‐cause mortality ( PSM : hazard ratio [ HR ] = 0.78, 95% confidence interval [ CI ]: 0.63–0.98, p = 0.03; IPTW : HR = 0.79, 95% CI : 0.64–0.97, p = 0.03). Statins also reduced the risk of thrombosis in this patient population ( PSM : HR = 0.63, 95% CI : 0.51–0.78, p < 0.01; IPTW : HR = 0.57, 95% CI : 0.49–0.66, p < 0.01) as well as in PV and ET subgroups.

Conclusions

These findings suggest that it may be important to incorporate statins into the therapeutic strategy for older adults with PV and ET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraThrombocythemia, EssentialHydroxymethylglutaryl-CoA Reductase InhibitorsThrombosisUnited StatesHumansAgedIncidenceCohort StudiesRisk FactorsMedicare

Stichwörter der Autor:innen

MPNstatinssurvivalthrombosis

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut, USA.
  • Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
  • Section of Cardiology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Nikolai A Podoltsev, Rory M Shallis, Scott F Huntington, Smith Giri

Förderung

  • NCCDPHP CDC HHS
  • NCATS NIH HHS
  • NCI NIH HHS
  • Frederick A. DeLuca Foundation

Zitieren

APA

Podoltsev, N. A., Wang, R., Shallis, R. M., Stempel, J. M., Di, M., Neparidze, N., Zeidan, A. M., Huntington, S. F., Giri, S., Hull, S. C., Gore, S. D., & Ma, X. (2023). Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine, 12(18), 18889-18900. https://doi.org/10.1002/cam4.6528

Vancouver

Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, et al. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine. 2023;12(18):18889-18900. doi:10.1002/cam4.6528

BibTeX
@article{Podoltsev2023,
  author = {Podoltsev, Nikolai A and Wang, Rong and Shallis, Rory M and Stempel, Jessica M and Di, Mengyang and Neparidze, Natalia and Zeidan, Amer M and Huntington, Scott F and Giri, Smith and Hull, Sarah C and Gore, Steven D and Ma, Xiaomei},
  title = {Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {18},
  pages = {18889--18900},
  doi = {10.1002/cam4.6528}
}
Kostenlos starten →